Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200666 | 0.88 | JAK3 (0.37) | JAK3JAK1 | |
| SCHEMBL31200652 | 0.86 | GPR119 (0.41) | — | |
| SCHEMBL31200682 | 0.83 | HRH3 (0.36) | — | |
| SCHEMBL31200816 | 0.80 | JAK1 (0.41) | JAK3JAK1HCRTR1HCRTR2 | |
| SCHEMBL31199443 | 0.79 | JAK3 (0.40) | JAK3JAK1HCRTR1HCRTR2 | |
| SCHEMBL31199326 | 0.79 | JAK3 (0.40) | JAK3JAK1HCRTR1HCRTR2 | |
| SCHEMBL31200706 | 0.75 | CHRNB2 (0.41) | — | |
| SCHEMBL29270326 | 0.75 | JAK3 (0.40) | JAK3JAK1BTKHCRTR1HCRTR2 | |
| SCHEMBL31200552 | 0.75 | USP30 (0.38) | JAK3 | |
| SCHEMBL31200583 | 0.75 | JAK3 (0.48) | JAK3JAK1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | JAK3 1770/4885JAK1 2226/4885BTK 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.